Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,693,066
  • Shares Outstanding, K 91,074
  • Annual Sales, $ 21,700 K
  • Annual Income, $ -123,630 K
  • 60-Month Beta 2.58
  • Price/Sales 76.47
  • Price/Cash Flow N/A
  • Price/Book 6.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.52
  • Number of Estimates 7
  • High Estimate -0.45
  • Low Estimate -0.63
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -79.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.51 +29.63%
on 11/11/19
19.30 -2.54%
on 12/09/19
+3.63 (+23.91%)
since 11/08/19
3-Month
9.73 +93.32%
on 10/09/19
19.30 -2.54%
on 12/09/19
+5.79 (+44.47%)
since 09/10/19
52-Week
5.14 +265.95%
on 12/24/18
19.30 -2.54%
on 12/09/19
+12.08 (+179.49%)
since 12/10/18

Most Recent Stories

More News
Tg Therapeutics has the Best Relative Performance in the Biotechnology Industry (TGTX , DVAX , EPZM , AGIO , CLVS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

DVAX : 6.89 (+4.55%)
EPZM : 18.81 (+1.18%)
TGTX : 9.42 (+1.51%)
Epizyme Inc Shares Up 60.8% Since SmarTrend's Buy Recommendation (EPZM)

SmarTrend identified an Uptrend for Epizyme Inc (NASDAQ:EPZM) on November 1st, 2019 at $11.70. In approximately 1 month, Epizyme Inc has returned 60.75% as of today's recent price of $18.80.

EPZM : 18.81 (+1.18%)
Cancer Drug Revenues Expected to be Largest Share in Pharma Market

One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8...

ONCY : 1.10 (-1.79%)
ONC.TO : 1.45 (-0.68%)
EPZM : 18.81 (+1.18%)
LXRX : 5.15 (+3.41%)
ABBV : 86.56 (+0.14%)
BMY : 62.09 (+1.32%)
Shares of Epizyme Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (EPZM , CLVS , SAGE , MNTA , ESPR )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CLVS : 12.10 (+12.98%)
EPZM : 18.81 (+1.18%)
SAGE : 63.29 (+1.01%)
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual...

EPZM : 18.81 (+1.18%)
Epizyme Inc Set to Possibly Pullback After Yesterday's Rally of 11.01%

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $16.31 to a high of $17.66. Yesterday, the shares gained 11.0%, which took the trading range above the 3-day high of $16.08...

EPZM : 18.81 (+1.18%)
Epizyme Announces FDA Committee Review of Tazemetostat NDA

Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.

GSK : 46.15 (+1.14%)
RHHBY : 38.4000 (+0.01%)
ALKS : 21.57 (-0.78%)
EPZM : 18.81 (+1.18%)
Implied Volatility Surging for Epizyme (EPZM) Stock Options

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

EPZM : 18.81 (+1.18%)
Look for Shares of Epizyme Inc to Potentially Rebound after Yesterday's 4.42% Sell Off

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $15.01 to a high of $16.52. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $16.37...

EPZM : 18.81 (+1.18%)
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug...

EPZM : 18.81 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 19.49
1st Resistance Point 19.15
Last Price 18.81
1st Support Level 18.43
2nd Support Level 18.05

See More

52-Week High 19.30
Last Price 18.81
Fibonacci 61.8% 13.89
Fibonacci 50% 12.22
Fibonacci 38.2% 10.55
52-Week Low 5.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar